Market Cap N/A
Revenue (ttm) 46.92M
Net Income (ttm) -38.10M
EPS (ttm) N/A
PE Ratio N/A
Forward PE 0.00
Profit Margin -81.20%
Debt to Equity Ratio N/A
Volume 775,700
Avg Vol 145,364
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclero...

Industry: Biotechnology
Sector: Healthcare
Phone: 778 731 1711
Website: nervgen.com
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Andy5700
Andy5700 Sep. 3 at 10:54 AM
$NGEN will we be sdvised in advance of any future dilution or are they not oblged to do so?
1 · Reply
Tarquinjones
Tarquinjones Sep. 3 at 5:13 AM
$NGEN yeah. Perhaps they replace the absolute bag of shit PR firm and manage to turn this into the national story it should and can be.
0 · Reply
MaxDragonMan
MaxDragonMan Sep. 3 at 5:10 AM
$NGEN Exciting getting confirmation enrollment starts this month. We were kind of expecting it, but still - seeing the movement and information of the last month has been super encouraging. Here's hoping our luck continues!
0 · Reply
BenUnknown
BenUnknown Sep. 3 at 2:52 AM
$NGEN Really encouraged by the NCT phase 3 posting today. 18 sites to kick things off is a blessing too! Looking forward to it all gents!!🥂
1 · Reply
AuriniaBeach
AuriniaBeach Sep. 3 at 1:02 AM
$NGEN Thank you to @Skaped who started a list of the first 18 likely study locations. I poked around some and found the likely facilities marked as “unknown” and updated his list.
0 · Reply
Rexpower
Rexpower Sep. 2 at 9:04 PM
$NGEN I am very happy the trial will officially begin recruiting soon. 18 centers is lower than I was hoping and no NYC seems odd. A little over 8 people per center. Wont be too long. LETS GO!!!
4 · Reply
Floridaorange
Floridaorange Sep. 2 at 7:36 PM
$NGEN Looks like July 2027 is now the date to circle for primary completion. And given the Week-12 primary endpoint, that’s a noticeably faster RESTORE timetable than we had previously been working with.
2 · Reply
Skaped
Skaped Sep. 2 at 7:22 PM
$NGEN Additional items confirmed via NCT: These participant requirements are officially dropped for RESTORE: -Participants capable of taking one step "unassisted" -MEP testing for two target muscle groups (no more MEP testing) -MRI-compatibility exclusions (no more MRI imaging) New requirements: -GRASSP combined QtP score under 34 (maximum score is 40) -Prior CNS gene therapy not permitted -ISNCSCI grade ≥1, L2–S1, either side -> this means the participant can twitch / flicker any muscle in either of their legs. This is far more accommodating than taking one step.
1 · Reply
Skaped
Skaped Sep. 2 at 6:07 PM
$NGEN Here is my AI's best guess for the 18 listed clinical trial sites from the NCT listing. The Shirley Ryan lab is not listed - perhaps they already used up the easy-to-find candidates in the area during CONNECT.
4 · Reply
BenUnknown
BenUnknown Sep. 2 at 6:06 PM
$NGEN LETS GO!!
0 · Reply
Latest News on NGEN
NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year

2026-08-17T07:59:09.000Z - 17 days ago

NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year


NervGen Pharma Earnings release: Q2 2026

Aug 13, 2026, 9:00 AM EDT - 20 days ago

NervGen Pharma Earnings release: Q2 2026


NervGen Pharma initiated with an Outperform at Leerink

2026-07-13T11:45:36.000Z - 7 weeks ago

NervGen Pharma initiated with an Outperform at Leerink


NervGen Pharma initiated with a Buy at TD Cowen

2026-06-11T09:51:08.000Z - 2 months ago

NervGen Pharma initiated with a Buy at TD Cowen


NervGen Pharma files $250M mixed securities shelf

2026-05-26T13:28:30.000Z - 3 months ago

NervGen Pharma files $250M mixed securities shelf


NervGen Pharma Registration statement: Registration filing

May 26, 2026, 8:00 AM EDT - 3 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma 24M share Spot Secondary priced at $2.50

2026-05-22T10:31:38.000Z - 3 months ago

NervGen Pharma 24M share Spot Secondary priced at $2.50


NervGen Pharma secondary being re-offered at $2.50 per share

2026-05-21T23:20:11.000Z - 3 months ago

NervGen Pharma secondary being re-offered at $2.50 per share


NervGen Pharma announces common share offering, no amount given

2026-05-21T20:06:04.000Z - 3 months ago

NervGen Pharma announces common share offering, no amount given


NervGen Announces Proposed Public Offering of Securities

May 21, 2026, 4:01 PM EDT - 3 months ago

NervGen Announces Proposed Public Offering of Securities


NervGen Pharma Slides: Corporate presentation

May 21, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Slides: Corporate presentation


NervGen Pharma reports Q1 EPS (2c), consensus (7c)

2026-05-18T11:26:55.000Z - 3 months ago

NervGen Pharma reports Q1 EPS (2c), consensus (7c)


NervGen Pharma Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Earnings release: Q1 2026


NervGen Pharma appoints Keith Vendola as CFO

2026-04-27T11:49:46.000Z - 4 months ago

NervGen Pharma appoints Keith Vendola as CFO


NervGen Pharma initiated with a Buy at H.C. Wainwright

2026-04-27T10:13:14.000Z - 4 months ago

NervGen Pharma initiated with a Buy at H.C. Wainwright


NervGen Pharma Transcript: HCW Home with NervGen Conference

Apr 15, 2026, 7:00 AM EDT - 4 months ago

NervGen Pharma Transcript: HCW Home with NervGen Conference


NervGen Pharma initiated with a Buy at Lucid Capital

2026-04-15T10:11:00.000Z - 4 months ago

NervGen Pharma initiated with a Buy at Lucid Capital


NervGen Pharma price target raised to $12 from $10 at Maxim

2026-04-08T19:20:16.000Z - 4 months ago

NervGen Pharma price target raised to $12 from $10 at Maxim


NervGen Pharma Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 5 months ago

NervGen Pharma Annual report: Q4 2025


NervGen Pharma Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 5 months ago

NervGen Pharma Earnings release: Q4 2025


NervGen Pharma to delist shares from TSX

2026-03-12T21:20:54.000Z - 5 months ago

NervGen Pharma to delist shares from TSX


NervGen Pharma price target raised to C$6.75 from C$5 at Stifel

2026-03-05T17:15:53.000Z - 6 months ago

NervGen Pharma price target raised to C$6.75 from C$5 at Stifel


NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 18, 2026, 7:30 AM EST - 6 months ago

NervGen Pharma to Participate at Upcoming Investor Conferences


NervGen Pharma Begins Trading on Nasdaq Today

Jan 8, 2026, 6:30 AM EST - 7 months ago

NervGen Pharma Begins Trading on Nasdaq Today


NervGen Pharma Registration statement: Registration filing

Jan 7, 2026, 7:00 AM EST - 7 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Registration statement: Registration filing

Dec 17, 2025, 7:00 AM EST - 8 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Announces Proposed Amendment to Warrants

Dec 12, 2025, 7:51 PM EST - 8 months ago

NervGen Pharma Announces Proposed Amendment to Warrants


NervGen Pharma Earnings release: Q3 2025

Nov 25, 2025, 7:00 AM EST - 9 months ago

NervGen Pharma Earnings release: Q3 2025


NervGen Pharma Earnings release: Q2 2025

Aug 26, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q2 2025


NervGen Pharma Grants Stock Options

May 16, 2025, 4:30 PM EDT - 1 year ago

NervGen Pharma Grants Stock Options


NervGen Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q1 2025


NervGen Pharma Earnings release: Q4 2024

Apr 3, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q4 2024


NervGen Initiates Expanded Access Policy

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy


NervGen Pharma to Host Virtual Investor Event

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event


NervGen Announces "At-The-Market" Equity Program

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program


NervGen Pharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NervGen Pharma Earnings release: Q3 2024


Andy5700
Andy5700 Sep. 3 at 10:54 AM
$NGEN will we be sdvised in advance of any future dilution or are they not oblged to do so?
1 · Reply
Tarquinjones
Tarquinjones Sep. 3 at 5:13 AM
$NGEN yeah. Perhaps they replace the absolute bag of shit PR firm and manage to turn this into the national story it should and can be.
0 · Reply
MaxDragonMan
MaxDragonMan Sep. 3 at 5:10 AM
$NGEN Exciting getting confirmation enrollment starts this month. We were kind of expecting it, but still - seeing the movement and information of the last month has been super encouraging. Here's hoping our luck continues!
0 · Reply
BenUnknown
BenUnknown Sep. 3 at 2:52 AM
$NGEN Really encouraged by the NCT phase 3 posting today. 18 sites to kick things off is a blessing too! Looking forward to it all gents!!🥂
1 · Reply
AuriniaBeach
AuriniaBeach Sep. 3 at 1:02 AM
$NGEN Thank you to @Skaped who started a list of the first 18 likely study locations. I poked around some and found the likely facilities marked as “unknown” and updated his list.
0 · Reply
Rexpower
Rexpower Sep. 2 at 9:04 PM
$NGEN I am very happy the trial will officially begin recruiting soon. 18 centers is lower than I was hoping and no NYC seems odd. A little over 8 people per center. Wont be too long. LETS GO!!!
4 · Reply
Floridaorange
Floridaorange Sep. 2 at 7:36 PM
$NGEN Looks like July 2027 is now the date to circle for primary completion. And given the Week-12 primary endpoint, that’s a noticeably faster RESTORE timetable than we had previously been working with.
2 · Reply
Skaped
Skaped Sep. 2 at 7:22 PM
$NGEN Additional items confirmed via NCT: These participant requirements are officially dropped for RESTORE: -Participants capable of taking one step "unassisted" -MEP testing for two target muscle groups (no more MEP testing) -MRI-compatibility exclusions (no more MRI imaging) New requirements: -GRASSP combined QtP score under 34 (maximum score is 40) -Prior CNS gene therapy not permitted -ISNCSCI grade ≥1, L2–S1, either side -> this means the participant can twitch / flicker any muscle in either of their legs. This is far more accommodating than taking one step.
1 · Reply
Skaped
Skaped Sep. 2 at 6:07 PM
$NGEN Here is my AI's best guess for the 18 listed clinical trial sites from the NCT listing. The Shirley Ryan lab is not listed - perhaps they already used up the easy-to-find candidates in the area during CONNECT.
4 · Reply
BenUnknown
BenUnknown Sep. 2 at 6:06 PM
$NGEN LETS GO!!
0 · Reply
OldManLogan
OldManLogan Sep. 2 at 6:06 PM
$NGEN Awesome. It shows September 23 as the study start date, which is good. It's critical to me that they have officially started the study ahead of the SCI PFDD meeting on the 29TH. The amount of free advertising that Nervgen will now be getting on 17th and 29th of this month is truly impressive...
0 · Reply
Skaped
Skaped Sep. 2 at 5:54 PM
$NGEN Good news! The NCT is officially live. https://clinicaltrials.gov/study/NCT07799532 https://nervgen.com/clinical-trials-expanded-access-policy/
2 · Reply
Westjtter
Westjtter Sep. 2 at 4:14 PM
$NGEN I picked up some shares at market, and also trying to get some limit buys which seem to be tough to get at anything lower than the current trading price. Will continue to pick up shares on any dip throughout the day.
0 · Reply
Westjtter
Westjtter Sep. 2 at 4:11 PM
$NGEN Yes insiders sell for a number of reasons...fwiw, these are all prearranged sales in general. Krista has sold about 80,000 shares earlier this year in the $4 range. Meanwhile Adam Rogers has made three huge buys...857,000 and 952,000 in November of last year and another 800,000 in June. I always take insider selling and buying with a grain of salt in any event as anyone with any insider information has to file basically a year in advance of any share sale. In most cases these are options that are vested and have tax implications and thus sales....in some cases they are to build a swimming pool! lol
0 · Reply
BenUnknown
BenUnknown Sep. 2 at 2:55 PM
$NGEN Anyone notice that Krista Mckerracher & Randall Kaye had uninformed sells yesterday? Nothing absurd and it looks like they each exercised options and sold a large chunk of the exercise. Doesn’t worry me, people need money for a plethora of reasons, figured I’d share
3 · Reply
OldManLogan
OldManLogan Sep. 2 at 12:44 PM
$NGEN Thanks for sharing, read this on the weekend and concluded, as you did, that the two approaches are definitely synergistic, though, research into the AHR pathway is several years behind us. One day though it could enhance NVG-291 's results... essentially we clear the road of any blockages and AHR revs the engine...
0 · Reply
Floridaorange
Floridaorange Sep. 2 at 11:53 AM
$NGEN **New confirmation: the official ⁠BreakThru SCI September 17 Congressional Briefing page has now explicitly added a “Clinical Trial Participant Panel — Voices from the NervGen Clinical Trial.” BreakThru states that people with SCI who participated in the NervGen clinical trial will speak at the Congressional briefing about their experiences, perspectives and hopes for SCI treatment. This is materially stronger than the previous generic wording. There is another speaker-list change: Dr. Geoffrey T. Manley, UCSF professor, Zuckerberg San Francisco General chief of neurosurgery and neurotrauma researcher, is now formally listed alongside Janet Woodcock and moderator Gavin Proffitt.
2 · Reply
Floridaorange
Floridaorange Sep. 2 at 10:05 AM
$NGEN Brad Lang, Case Western — April 2026: “The results were unbelievable to me as someone in the field.” He immediately explains why: “There’s never a solution or a drug that has ever worked for repairing spinal cord injury.” Lang worked with Jerry Silver’s group on the PTPσ/CSPG biology underlying what became NVG-291. He also describes the original discovery process: they identified one peptide out of twelve that worked, thought the result might be too good to be true, and then spent three years validating it across additional nerve and SCI models. He says it “consistently worked.”
0 · Reply
aladdinscarpet
aladdinscarpet Sep. 2 at 3:31 AM
$NGEN this is interesting as a possible complement to NVG-291 far in the future… https://www.sciencedaily.com/releases/2026/08/260828005427.htm
1 · Reply
Bmrupert
Bmrupert Sep. 2 at 12:40 AM
$NGEN If only I knew of a peptide that would help our veterans…😉
1 · Reply
OldManLogan
OldManLogan Sep. 2 at 12:19 AM
$NGEN I believe we are heading towards closing the gap at $3.60... I'm calling that Price Objective "the appetizer " lol
1 · Reply
Skaped
Skaped Sep. 1 at 11:13 PM
$NGEN will NVG-291 receive breakthrough therapy designation?
1 · Reply